First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease
Journal of Nuclear Medicine
2015
57
2
248-251
Complementary, Selective PET Imaging of Integrin Subtypes 5 1 and v 3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin
Journal of Nuclear Medicine
2015
57
3
460-466
Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI
Journal of Nuclear Cardiology
2015
23
1
131-133
Comparison of [11C]Choline ([11C]CHO) and [18F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model
Molecular Imaging and Biology
2015
18
3
393-401
Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas
European Journal of Nuclear Medicine and Molecular Imaging
2015
43
1
133-141
In vivo biokinetic and metabolic characterization of the 68Ga-labelled α5β1-selective peptidomimetic FR366
European Journal of Nuclear Medicine and Molecular Imaging
2015
43
5
953-963
Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging
Theranostics
2015
618-630
The Influence of the Combination of Carboxylate and Phosphinate Pendant Arms in 1,4,7-Triazacyclononane-Based Chelators on Their 68Ga Labelling Properties
Molecules
2015
20
13112-13126
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
Journal of Nuclear Medicine
2015
56
1169-1176
Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy
Journal of Nuclear Medicine
2015
56
855-861